Clinical Trial Update: COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and pharmacokinetics of EIDD-2801 in healthy volunteers has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus

Drugs mentioned

• EIDD-2801 (molnupiravir)

Snippet

Sponsor: Ridgeback Biotherapeutics, LP | Conditions: Coronavirus | Phase 1 | Status: COMPLETED | Results posted: 2021-07-19